Biologic agents in nail psoriasis: efficacy data and considerations

Bibliography

• Aktan S, Ilknur T, Akin C, et al. Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol 2007;32:141-4
   PubMed Web of Science ®Google Scholar
• Armesto S, Esteve A, Coto-Segura P, et al. Nail psoriasis in individuals with psoriasis vulgaris: a study of 661 patients. Actas Dermosifiliogr 2011;102:365-72
   PubMedGoogle Scholar
• Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010;163:580-5
   PubMed Web of Science ®Google Scholar
• Baran RL. A nail psoriasis severity index. Br J Dermatol 2004;150:568-9
   PubMed Web of Science ®Google Scholar
• Brazzelli V, Carugno A, Alborghetti A, et al. Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience. J Eur Acad Dermatol Venereol 2011
   Web of Science ®Google Scholar
• de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996;193:300-3
   PubMed Web of Science ®Google Scholar
• Grover C, Reddy BS, Uma CK. Diagnosis of nail psoriasis: importance of biopsy and histopathology. Br J Dermatol 2005;153:1153-8
   PubMed Web of Science ®Google Scholar
• Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27
   PubMed Web of Science ®Google Scholar
• Kyriakou A, Patsatsi A, Sotiriadis D. Detailed analysis of specific nail psoriasis features and their correlations with clinical parameters: a cross-sectional study. Dermatology 2011;223:222-9
   PubMed Web of Science ®Google Scholar
• Langley RG, Dauden E. Treatment and management of psoriasis with nail involvement: a focus on biologic therapy. Dermatology 2010;221(Suppl 1):29-42
   PubMedGoogle Scholar
• Radtke MA, Langenbruch AK, Schafer I, et al. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas 2011;2:1-6
   PubMedGoogle Scholar
• Tan ES, Chong WS, Tey HL. Nail psoriasis: a review. Am J Clin Dermatol 2012;13:375-88
   PubMed Web of Science ®Google Scholar
• Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009;23(Suppl 1):15-21
   PubMed Web of Science ®Google Scholar
• Baran R. The burden of nail psoriasis: an introduction. Dermatology 2010;221(Suppl 1):1-5
   PubMed Web of Science ®Google Scholar
• Soy M, Karaca N, Umit EU, et al. Joint and nail involvement in Turkish patients with psoriatic arthritis. Rheumatol Int 2008;29:223-5
   PubMed Web of Science ®Google Scholar
• Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis–clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004;43:790-4
   PubMed Web of Science ®Google Scholar
• Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12
   PubMed Web of Science ®Google Scholar
• Augustin M, Ogilvie A. Methods of outcomes measurement in nail psoriasis. Dermatology 2010;221(Suppl 1):23-8
   PubMedGoogle Scholar
• Parrish CA, Sobera JO, Elewski BE. Modification of the Nail Psoriasis Severity Index. J Am Acad Dermatol 2005;53:745-6
   PubMed Web of Science ®Google Scholar
• Radtke MA, Beikert FC, Augustin M. Nail psoriasis - a treatment challenge. J Dtsch Dermatol Ges 2013;11:203-19
   PubMed Web of Science ®Google Scholar
• Langley RG, Saurat JH, Reich K. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol 2012;26:373-81
   PubMed Web of Science ®Google Scholar
• Irla N, Yawalkar N. Marked improvement in nail psoriasis during treatment with adalimumab. Dermatology 2009;219:353-6
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010;24:530-4
   PubMed Web of Science ®Google Scholar
• Sola-Ortigosa J, Sanchez-Regana M, Umbert-Millet P. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice. J Dermatolog Treat 2012;23:203-7
   PubMed Web of Science ®Google Scholar
• Paul C, van de Kerkhof P, Puig L, et al. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. Eur J Dermatol 2012;22:762-9
   PubMed Web of Science ®Google Scholar
• Rallis E, Stavropoulou E, Rigopoulos D, et al. Rapid response of nail psoriasis to etanercept. J Rheumatol 2008;35:544-5
   PubMed Web of Science ®Google Scholar
• Barrera MV, Habicheyn S, Mendiola MV, et al. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008;18:683-7
   PubMed Web of Science ®Google Scholar
• Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009;23:896-904
   PubMed Web of Science ®Google Scholar
• Coelho JD, Diamantino F, Lestre S, et al. Treatment of severe nail psoriasis with etanercept. Indian J Dermatol Venereol Leprol 2011;77:72-4
   PubMed Web of Science ®Google Scholar
• Gomez VM, Navarra AR. Marked improvement in nail psoriasis during treatment with etanercept. Dermatol Ther 2011;24:498-500
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Paul C, Berardesca E, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol 2012
   Web of Science ®Google Scholar
• Bianchi L, Bergamin A, de FC, et al. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005;52:736-7
   PubMed Web of Science ®Google Scholar
• Safa G, Darrieux L. Dramatic response of nail psoriasis to infliximab. Case Rep Med 2011;2011:107928
   Google Scholar
• Hussain W, Coulson I, Owen C. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients. Clin Exp Dermatol 2008;33:520-2
   PubMed Web of Science ®Google Scholar
• Fabroni C, Gori A, Troiano M, et al. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. J Eur Acad Dermatol Venereol 2011;25:549-53
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008;159:453-6
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
   PubMed Web of Science ®Google Scholar
• Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008;58:224-31
   PubMed Web of Science ®Google Scholar
• Reich K, Ortonne JP, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology 2010;221:172-8
   PubMed Web of Science ®Google Scholar
• Rallis E, Kintzoglou S, Verros C. Ustekinumab for rapid treatment of nail psoriasis. Arch Dermatol 2010;146:1315-6
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Makris M, et al. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology 2011;223:325-9
   PubMed Web of Science ®Google Scholar
• Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J Dermatolog Treat 2013;24:96-100
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012;39:242-52
   PubMed Web of Science ®Google Scholar
• Sanchez-Regana M, Sola-Ortigosa J, Alsina-Gibert M, et al. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol 2011;25:579-86
   PubMed Web of Science ®Google Scholar
• Kyriakou A, Patsatsi A, Sotiriadis D. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study. J Dermatolog Treat 2013;24:162-8
   PubMed Web of Science ®Google Scholar
• Saraceno R, Pietroleonardo L, Mazzotta A, et al. TNF-alpha antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis. Expert Opin Biol Ther 2013;13:469-73
   PubMed Web of Science ®Google Scholar
• Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006;33:1452-6
   PubMed Web of Science ®Google Scholar
• de Vries AC, Bogaards NA, Hooft L, et al. Interventions for nail psoriasis. Cochrane Database Syst Rev 2013;1:CD007633
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 2013;22:993-1005
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168:412-21
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013;168:402-11
   PubMed Web of Science ®Google Scholar
• Zhu B, Edson-Heredia E, Cameron G, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase 2 study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2013
   PubMed Web of Science ®Google Scholar
• Reich K. Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. N Engl J Med 2012;367:274
   PubMedGoogle Scholar
• Spuls PI, Hooft L. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol 2012;167:710-3
   PubMed Web of Science ®Google Scholar
• Waisman A. To be 17 again-anti-interleukin-17 treatment for psoriasis. N Engl J Med 2012;366:1251-2
   PubMed Web of Science ®Google Scholar
• Wu JJ. Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. N Engl J Med 2012;367:274-5
   PubMedGoogle Scholar